absolutely Im not saying Anavex is not doing any investigation in their ongoing patient population trial in the why the OTHER 26 with lower doze didnt response as well as the 6. However there is zero reason why the FDA should not give a go ahead for the extended trial with 300 participants, as for A273 is very safe.
If all 300 are given the highest dose and the participants with high blood pressure have zero response (which they dont) and those with high blood pressure make up for 25% of the group and the other 75% of the group are responding very well, A273 will be SOC 10 times over....
The advantage of A273 in AD is that Donezepil is BS and AD is more or less an orphan drug.. IMO
I believe Missling's comment about efficacy being more pronounced for the mildly afflicted has much to do with the outliers. The ones at higher concentrations not stabilized were likely advanced in their disease. While the one performing well on a lower concentration was likely less advanced (mild).
Sure, DNA, RNA, gut biome, etc., could be factors within those disease stages, but early treatment would seem to be the biggest factor.
Market Data 
Markets 
AI
